UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $7.99 Million in Indivior PLC $INDV

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Indivior PLC (NASDAQ:INDV) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 194,687 shares of the company’s stock, valued at approximately $7,988,000.

A number of other large investors have also added to or reduced their stakes in INDV. Quarry LP bought a new stake in Indivior during the 3rd quarter worth approximately $26,000. Raymond James Financial Inc. acquired a new position in Indivior in the 2nd quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after acquiring an additional 460 shares during the last quarter. Rockefeller Capital Management L.P. lifted its holdings in shares of Indivior by 512.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock worth $46,000 after purchasing an additional 1,076 shares during the period. Finally, GAMMA Investing LLC acquired a new position in shares of Indivior during the second quarter worth $66,000. Institutional investors own 60.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on INDV shares. Barclays decreased their price objective on Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a report on Monday, June 29th. Weiss Ratings upgraded Indivior from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday. Finally, Craig Hallum reissued a “buy” rating and issued a $53.00 price target on shares of Indivior in a research note on Tuesday, August 4th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $45.17.

Indivior Stock Performance

INDV stock opened at $34.94 on Tuesday. The firm has a market cap of $4.12 billion, a PE ratio of 12.52 and a beta of 0.82. The stock has a 50-day moving average price of $38.64 and a 200-day moving average price of $36.04. Indivior PLC has a 1-year low of $22.22 and a 1-year high of $42.81.

Indivior (NASDAQ:INDV) last released its earnings results on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%.The business had revenue of $343.00 million during the quarter. On average, analysts forecast that Indivior PLC will post 3.66 earnings per share for the current year.

Insider Activity at Indivior

In other Indivior news, insider Christian Heidbreder sold 18,586 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $41.14, for a total transaction of $764,628.04. Following the transaction, the insider directly owned 209,337 shares in the company, valued at approximately $8,612,124.18. This represents a 8.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Woodrow D. Anderson acquired 1,500 shares of Indivior stock in a transaction dated Thursday, August 27th. The shares were bought at an average cost of $35.69 per share, with a total value of $53,535.00. Following the transaction, the chief accounting officer owned 27,638 shares in the company, valued at approximately $986,400.22. This trade represents a 5.74% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.74% of the stock is currently owned by insiders.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.